



April 13, 2020

Re: RestorOx™ efficacy against SARS-CoV-2, the virus which causes COVID-19 disease

Dear Sir or Madam,

In cases of emerging viral pathogens like SARS-CoV-2, the virus that causes COVID-19, when there is no test that can be conducted to validate the efficacy of a disinfectant, the EPA utilizes Emerging Viral Pathogen Guidance to determine the expected efficacy of a disinfectant against an emerging virus. This guidance, used previously during the 2003 SARS epidemic, mandates that for disinfectant products to be approved against an enveloped or non-enveloped virus, they must be an EPA registered Hospital or Broad-Spectrum disinfectant and have proven efficacy against two small, non-enveloped viruses, such as Poliovirus and Parvovirus. In the case of SARS-CoV-2, the following criteria are used to determine efficacy of a disinfectant upon activation of the Emerging Pathogen Rule:

1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA.
2. The product must have acceptable efficacy data previously submitted to and reviewed by the Agency against one non-enveloped virus (e.g. Poliovirus).

RestorOx™ Disinfectants fulfill these criteria and are included on the EPA's List N: Disinfectants for Use Against SARS-CoV-2. Simply search by the EPA Registration Number: 74559-9 (<https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>). RestorOx™ disinfectants can be used against SARS-CoV-2 as part of a facility's COVID-19 infection prevention and control plan on hard, non-porous surfaces. RestorOx™ should be applied with a 30-second contact time. Refer to the CDC website at www.cdc.gov/outbreaks/ for additional information.

Should you require any further information, please do not hesitate to contact me directly at 1-800-387-7578 ext. 118 or via email at nkenny@virox.com.

Best Regards,

Nicole Kenny, HBSc., Assoc Chem
Vice President, Professional and Technical Services
Virox Technologies Inc.

